Reverse Visually Guided Reaching in Patients with Parkinson’s Disease

Table 1

Characteristics of subjects with PD.

Participant code	Age (years)	Sex	Disease duration (years)	Years with DBS	PD medications	Levodopa equivalent dosages (mg/day)
PD01	48	M	0.5	N/A	Levodopa	600
PD02	55	M	6	N/A	Levodopa	600
PD03	71	M	5	N/A	Levodopa, stalevo	1332
PD04	67	M	5	N/A	Levodopa, rasagiline, pramipexole	825
PD05	70	M	15	N/A	Levoodpa, stalevo	1365
PD06	67	M	11	N/A	Levodopa, amantadine	600
PD07	55	M	3	N/A	Levodopa	550
PD08	72	M	13	N/A	Levodopa	350
PD09	57	M	4	N/A	Levodopa	600
PD10	69	M	6	N/A	Levodopa	875
PD11	72	M	8	N/A	Levodopa, pramipexole	550
PD12	70	F	5	N/A	Levodopa, stalevo	858
PD13	53	F	2	N/A	Levodopa	1100
PD14	61	F	3	N/A	Levodopa	300
PD15	73	M	3	N/A	Levodopa, pramipexole	900
PD16	75	M	8	N/A	Levodopa, pramipexole	950
PD17	69	F	5	N/A	Levodopa, pramipexole	700
PD18	72	M	5	N/A	Levodopa, pramipexole	1300
PD19	68	M	5	N/A	Levodopa, pramipexole	1125
PD20	75	M	3	N/A	Levodopa	950
PD21	58	M	5	N/A	Levodopa	600
PD22	54	F	4	N/A	Levodopa	450
PD23	75	F	8	N/A	Levodopa	600
PD24	47	M	3	N/A	Levodopa	450
PD25	64	M	6	N/A	Levodopa, rotigotine	1120
PD26	71	F	2	N/A	Levodopa	400
PD27	63	M	20	5	Levodopa, rotigotine	1170
PD28	56	M	19	3	Levodopa	2475
PD29	75	F	21	4	Levodopa	900
PD30	46	M	14	5	Levodopa, ropinirole	920
PD31	63	M	10	0.25	Levodopa, pramipexole, amantadine	476
PD32	77	F	16	7	Levodopa, pramipexole, rasageline	475
PD33	63	M	23	5	Levodopa	500